Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Nrx Pharmaceuticals Inc's Business Segments
Nrx Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 1
Regions Reported
-
Nrx Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - Q2 FY2026
- Therapy79.1%
- Procedures20.9%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Therapy | $ 1 | 79.1% |
| Procedures | $ 0 | 20.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Nrx Pharmaceuticals Inc
NRx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the research and development of innovative therapies for patients suffering from serious, devastating diseases. The company primarily focuses on neurological and psychiatric disorders, aiming to provide groundbreaking treatments that can improve the quality of life for those affected.
NRx Pharmaceuticals was founded in 2020 by renowned psychiatrist Dr. Jonathan Javitt and is headquartered in New York City, USA. Driven by a mission to address unmet medical needs, the company combines cutting-edge science, advanced technology, and a patient-centric approach to develop therapies that can have a significant impact on the lives of patients and their families.
The core therapeutic focus of NRx Pharmaceuticals lies in the development of novel drugs targeting the glutamatergic system, which plays a crucial role in various neurological and psychiatric disorders. Specifically, the company is involved in the development of NRX-101, a first-in-class intranasal formulation of ketamine, as a potential treatment for conditions such as major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and suicidal ideation.
NRX-101 has the potential to provide rapid-acting, long-lasting relief for patients suffering from these debilitating conditions. The company's approach involves leveraging ketamine's well-known antidepressant effects and refining its delivery to optimize therapeutic outcomes and minimize adverse side effects.
NRx Pharmaceuticals engages in rigorous clinical trials to evaluate the safety and efficacy of its drug candidates. The company has a strong collaborative network with academic institutions, research organizations, and leading experts in the field to ensure the highest scientific standards in its research and development efforts.
In addition to its focus on NRX-101, NRx Pharmaceuticals also explores other promising candidates in its pipeline. These include NRX-102, a potential therapy for bipolar depression, as well as other innovative compounds targeting neurological and psychiatric diseases.
NRx Pharmaceuticals is committed to advancing its therapies through the clinical development process as efficiently as possible to provide potentially life-changing treatments for patients in need. By actively collaborating with healthcare providers, advocacy groups, and regulatory authorities, the company strives to raise awareness about these devastating disorders and contribute to improving the standard of care.
Overall, NRx Pharmaceuticals Inc. is dedicated to transforming the lives of patients suffering from neurological and psychiatric disorders through innovative, science-driven therapies. With a strong focus on research, development, and collaboration, the company aims to bring hope and relief to those affected by these conditions.
NRx Pharmaceuticals was founded in 2020 by renowned psychiatrist Dr. Jonathan Javitt and is headquartered in New York City, USA. Driven by a mission to address unmet medical needs, the company combines cutting-edge science, advanced technology, and a patient-centric approach to develop therapies that can have a significant impact on the lives of patients and their families.
The core therapeutic focus of NRx Pharmaceuticals lies in the development of novel drugs targeting the glutamatergic system, which plays a crucial role in various neurological and psychiatric disorders. Specifically, the company is involved in the development of NRX-101, a first-in-class intranasal formulation of ketamine, as a potential treatment for conditions such as major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and suicidal ideation.
NRX-101 has the potential to provide rapid-acting, long-lasting relief for patients suffering from these debilitating conditions. The company's approach involves leveraging ketamine's well-known antidepressant effects and refining its delivery to optimize therapeutic outcomes and minimize adverse side effects.
NRx Pharmaceuticals engages in rigorous clinical trials to evaluate the safety and efficacy of its drug candidates. The company has a strong collaborative network with academic institutions, research organizations, and leading experts in the field to ensure the highest scientific standards in its research and development efforts.
In addition to its focus on NRX-101, NRx Pharmaceuticals also explores other promising candidates in its pipeline. These include NRX-102, a potential therapy for bipolar depression, as well as other innovative compounds targeting neurological and psychiatric diseases.
NRx Pharmaceuticals is committed to advancing its therapies through the clinical development process as efficiently as possible to provide potentially life-changing treatments for patients in need. By actively collaborating with healthcare providers, advocacy groups, and regulatory authorities, the company strives to raise awareness about these devastating disorders and contribute to improving the standard of care.
Overall, NRx Pharmaceuticals Inc. is dedicated to transforming the lives of patients suffering from neurological and psychiatric disorders through innovative, science-driven therapies. With a strong focus on research, development, and collaboration, the company aims to bring hope and relief to those affected by these conditions.
NRx Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative treatments for various clinical conditions, with a special emphasis on neuropsychiatric disorders and other high-need areas. The company is actively engaged in research and development, bringing forward new therapies aimed at addressing unmet medical needs.
Segments
1. Neuropsychiatric Disorders: This segment concentrates on the treatment of mental health conditions such as depression, anxiety, and bipolar disorders. NRx focuses on developing therapeutics that target the underlying neurological mechanisms of these disorders.
2. Acute Treatments: NRx is involved in creating treatments for acute psychiatric episodes, potentially including rapid-onset therapies that can be administrated in emergency care settings.
3. Infectious Diseases: In addition to neuropsychiatric treatments, NRx Pharmaceuticals is involved in addressing infectious diseases, focusing on conditions that significantly impact public health.
Products
1. NRX-101: One of the most prominent products in the pipeline, NRX-101 is an investigational drug that combines an established treatment for bipolar depression with a new molecular entity. It is designed to target the acute treatment of severe depression, particularly in patients with bipolar disorder.
2. NRX-102: This product is another investigational therapy aimed at the treatment of PTSD (Post-Traumatic Stress Disorder) and major depressive disorder. NRX-102 may leverage unique pharmacological action to offer quicker therapeutic effects.
3. NRX-201: A novel investigational therapy targeting conditions characterized by severe and persistent symptoms in neuropsychiatric disorders. It is aimed at providing a new option for patients who have individuals who have not responded adequately to existing treatments
Services
1. Clinical Trials and Research: NRx Pharmaceuticals is actively engaged in conducting clinical trials to evaluate the safety and efficacy of its products. This service includes designing and implementing trial protocols, recruiting participants, and collecting data.
2. Regulatory Affairs Consulting: The company may provide services to navigate the complex landscape of pharmaceutical regulations, which includes preclinical and clinical trial advice, submissions for Investigational New Drug (IND) applications, and New Drug Applications (NDA).
3. Collaboration and Partnerships: NRx often engages in strategic partnerships with other pharmaceutical companies, research institutions, and healthcare providers to foster innovation and bring new therapies to market.
4. Patient Support Programs: To ensure better outcomes for patients, NRx may offer support services including education on treatments, access to necessary resources, and collaborating with healthcare providers for optimal treatment plans.
Conclusion
In summary, NRx Pharmaceuticals Inc. is positioned in the biopharmaceutical sector with a focus on highly specialized segments dealing with neuropsychiatric disorders and acute treatments for infectious diseases. Its research and development efforts aim to bring innovative products to market through clinical trials and strategic partnerships, with supportive services targeted at regulatory navigation and patient care.
Segments
1. Neuropsychiatric Disorders: This segment concentrates on the treatment of mental health conditions such as depression, anxiety, and bipolar disorders. NRx focuses on developing therapeutics that target the underlying neurological mechanisms of these disorders.
2. Acute Treatments: NRx is involved in creating treatments for acute psychiatric episodes, potentially including rapid-onset therapies that can be administrated in emergency care settings.
3. Infectious Diseases: In addition to neuropsychiatric treatments, NRx Pharmaceuticals is involved in addressing infectious diseases, focusing on conditions that significantly impact public health.
Products
1. NRX-101: One of the most prominent products in the pipeline, NRX-101 is an investigational drug that combines an established treatment for bipolar depression with a new molecular entity. It is designed to target the acute treatment of severe depression, particularly in patients with bipolar disorder.
2. NRX-102: This product is another investigational therapy aimed at the treatment of PTSD (Post-Traumatic Stress Disorder) and major depressive disorder. NRX-102 may leverage unique pharmacological action to offer quicker therapeutic effects.
3. NRX-201: A novel investigational therapy targeting conditions characterized by severe and persistent symptoms in neuropsychiatric disorders. It is aimed at providing a new option for patients who have individuals who have not responded adequately to existing treatments
Services
1. Clinical Trials and Research: NRx Pharmaceuticals is actively engaged in conducting clinical trials to evaluate the safety and efficacy of its products. This service includes designing and implementing trial protocols, recruiting participants, and collecting data.
2. Regulatory Affairs Consulting: The company may provide services to navigate the complex landscape of pharmaceutical regulations, which includes preclinical and clinical trial advice, submissions for Investigational New Drug (IND) applications, and New Drug Applications (NDA).
3. Collaboration and Partnerships: NRx often engages in strategic partnerships with other pharmaceutical companies, research institutions, and healthcare providers to foster innovation and bring new therapies to market.
4. Patient Support Programs: To ensure better outcomes for patients, NRx may offer support services including education on treatments, access to necessary resources, and collaborating with healthcare providers for optimal treatment plans.
Conclusion
In summary, NRx Pharmaceuticals Inc. is positioned in the biopharmaceutical sector with a focus on highly specialized segments dealing with neuropsychiatric disorders and acute treatments for infectious diseases. Its research and development efforts aim to bring innovative products to market through clinical trials and strategic partnerships, with supportive services targeted at regulatory navigation and patient care.